Our Products

Cannabinoid Derived Therapeutics for Pets


CannPal is focused on developing and commercialising therapeutic prescription products (pharmaceuticals) as well as non-prescription products (nutraceuticals and dietary supplements) to address clear unmet needs for companion animals, using compounds derived from the cannabis plants.

Our active product pipeline contains two lead products in development targeting pain and inflammation in dogs, along with canine skin health, the two most prevalent disease categories in animal health. We also have active exploratory R&D programs for other disease states in collaboration with research partners.

We use naturally derived API’s (Active Pharmaceutical Ingredients) and a combination of whole plant extracts and isolated cannabinoid’s to develop our therapeutic products. You can learn more about cannabinoids here.

The active cannabinoids that we’re currently researching, are Cannabidiol (CBD) and Delta-9 Tetrahydrocannabinol (THC). We’re also actively researching other cannabinoid-like compounds that are derived from the cannabis plant in our research and development pipeline.

To learn more about our programs click to view details:

CPAT-01D – Pain Control in Dogs
PAT-01 is a cannabis-derived therapeutic product being developed to target pain and inflammation in companion animals, with a focus on dogs. The Company is researching the therapeutic potential of a proprietary combination of 2 cannabinoids, CBD (Cannabidiol) and THC  Tetrahydrocannabinol) in an optimized ratio to develop an oral liquid formulation with the hopes to receive regulatory approval to allow for veterinarians to provide pet owners with legal access to cGMP produced and safe cannabinoid-derived treatment for pets.

It’s estimated that the current market size for pain and inflammation drugs for dogs is worth over USD $1.4b and growing at a CAGR of over 4%. However In the last decade, animal health manufacturers only had an average of seven NCE (new chemical entity) approvals per year, down from 12 per year in the prior decade in the entire animal health sector, despite spending twice as much on R&D. This shows a clear gap in innovation.

NSAID’s have traditionally been the most common treatment for pain in dogs, estimated in over 83% of sales for pain in 2015, but these products can include a long list of negative reported side effects which make them undesirable for long term use, with a private survey provided on over 300 veterinarians in the United States showing that an estimated 50% are concerned with the side effects in NSAID’s.

CannPal hopes to develop a product that can offer veterinarians an alternative or adjunctive therapy for pain and inflammation in companion animals to reduce the amount of potentially unsafe therapeutics used in practise.
DermaCann – Canine Skin Health
Allergic skin conditions are one of the most widely reported diseases in companion animals. It’s reported that almost 20% of all pets have a skin condition that requires treatment. Furthermore, skin health is a priority disease state for pet owners and is the second largest market in companion animals for dietary supplements. 

In a proprietary CannPal survey of 300 veterinarians in the US, it was reported that an average of 14.2 new allergic skin condition cases were seen each month per veterinarian in dogs and the condition scored a 4.3 out of 5 as a negative perceived impact to quality of life for Allergic Skin Conditions, only topped by Osteoarthritis and Chronic Pain, each with 4.4 and 4.3 respectively.

The primary treatment option for allergic and skin inflammatory diseases in animals can often be inhibited by their side effects profiles which can restrict long term use. Other treatment alternatives are inhibited by their cost or are undesirable due to their ineffectiveness.

CannPal is developing a range of nutraceutical products tailored towards disease states in companion animals, with DermaCann being developed as a lead therapeutic product for promoting optimal skin health in dogs using compounds from the hemp plant which is one of the richest sources of Omega 3 and 6, along with proprietary ingredients targeted towards treating skin disease in dogs.
Other R&D
CannPal has entered into additional research collaborations with multiple partners to continue building on it’s expertise in therapeutics derived from cannabinoids and enhancing the delivery of the Company’s products. Some of these partnerships include:

CSIRO
CannPal entered into a research agreement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) under the CSIRO Kick-Start initiative. CSIRO Kick-Start was launched in April 2017, providing innovative Australian start-ups and SMEs with funding support and access to CSIRO’s research expertise and facilities. The program offers eligible businesses access to:

– Research into a new idea with commercial potential;
– Development of a novel or improved product or process; or
– The testing of a novel product or material developed by the business.

Under the initiative CSIRO and CannPal will undertake initial research into formulation work. CannPal intends to further develop new and existing delivery systems to create proprietary formulations of the Company’s therapeutic products, which CannPal management believes could provide a significant competitive advantage.

The University of Melbourne
The Company has entered into a Memorandum of Understanding (MOU) with The University of Melbourne (‘the University’) to broaden CannPal’s research pipeline.

Under the terms of MOU, CannPal and the University will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol (CBD) treatment for epilepsy in dogs. Cannabidiol is a non-psychoactive compound derived from cannabis with a number of reported health benefits which include anxiolytic, antiinflammatory, antibacterial and antiseizure properties.

The Company hopes to commence R&D activities as part of the collaboration in 2019.

CPAT-01C for Cats
The Company has entered into a research and services agreement with a leading feline veterinary research organisation to test the Company’s lead drug candidate, CPAT-01, in cats.

Cats represent over 25% of the companion animal drug market and there’s a clear unmet need for safe therapeutics that can be used long term to treat pain and inflammation in felines.